Metastatic Castration-resistant Prostate Cancer Clinical Trials in Dallas, Texas

6 studies are recruiting for metastatic castration-resistant prostate cancer in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

   The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   155 in total

   Run by

   Amgen

   See if you can join NCT07213674 on ClinicalTrials.gov

2. Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI at Mary Crowley, Dallas, Texas

   Locations

   6 in total

   Run by

   Janux Therapeutics

   See if you can join NCT07545811 on ClinicalTrials.gov

3. A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

   Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castra…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Urology Clinics Of North Texas, Dallas, Texas

   Locations

   7 in total

   Run by

   ORIC Pharmaceuticals

   See if you can join NCT07723248 on ClinicalTrials.gov

4. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

   The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior secon…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   23 in total

   Run by

   Kyntra Bio

   See if you can join NCT06842498 on ClinicalTrials.gov

5. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Mary Crowley Cancer Research, Dallas, Texas

   Locations

   36 in total

   Run by

   Janux Therapeutics

   See if you can join NCT05519449 on ClinicalTrials.gov

6. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

   Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Urology Clinics of North Texas, Dallas, Texas

   Locations

   25 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT04729114 on ClinicalTrials.gov